Why take the continuous route? Because it leads to better, faster bioprocessing.
Sponsored By
Why adopt continuous bioprocessing? Because it can lead to faster and more cost-effective biopharma manufacturing. In this supplement, Pall and their collaborators discuss the benefits of continuous bioprocessing and how Pall is innovating in this area.
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
September 28, 2026
2 min read
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
September 9, 2026
5 min read
Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
August 31, 2026
4 min read
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products